Nutriband Inc. has reported its financial results for the third quarter and the nine months ending October 31, 2025, revealing a significant decline in revenue and an increase in net losses compared to the same period in the previous year. The company generated revenue of $346,058 for the three months ended October 31, 2025, down from $645,796 in the same quarter of 2024. For the nine-month period, revenue increased to $1,635,942 from $1,497,158 year-over-year. Despite this increase in nine-month revenue, the company reported a net loss of $3,872,367 for the third quarter, compared to a loss of $1,362,637 in the prior year, and a total net loss of $7,261,573 for the nine months, up from $4,966,179.
The financial performance reflects a notable increase in selling, general, and administrative expenses, which rose to $3,491,728 in the third quarter from $737,102 in the same period last year. This increase is attributed primarily to higher legal, accounting, and compensation expenses. Research and development costs for the Aversa Fentanyl product also decreased to $457,113 from $880,768 year-over-year, indicating a shift in focus and a winding down of previous contracts. The company’s gross profit for the nine months was $477,367, compared to $453,373 in the prior year, suggesting improved margins despite the overall losses.
Nutriband has made strategic moves to enhance its operational capabilities, including the acquisition of additional equipment to meet new demand in its Pocono Pharmaceuticals segment. However, the company has faced challenges, including a significant customer moving operations overseas, which has impacted revenue generation. The company has also been active in financing, raising $5,305,503 from the exercise of warrants during the nine months, contributing to a cash position of $5,312,177 as of October 31, 2025.
Looking ahead, Nutriband's management remains optimistic about its ability to generate sufficient funds to support operations for at least the next year. The company is focused on advancing its Aversa product line, which is designed to deter abuse of transdermal pharmaceuticals. The recent partnership with Kindeva Drug Delivery aims to enhance the development of Aversa Fentanyl, with expectations for future growth in demand as the company continues to refine its product offerings. Despite the current financial challenges, management believes that the strategic initiatives in place will position the company for improved performance in the future.
About NutriBand Inc.
Nutriband Inc. develops transdermal pharmaceutical products, focusing on abuse-deterrent patches for opioids and stimulants. Its core technology, AVERSA, aims to reduce drug abuse, misuse, and accidental exposure. The company collaborates with contract manufacturers and research organizations, targeting markets in the U.S. and internationally. Its business model emphasizes innovative drug delivery systems, regulatory approval pathways, and intellectual property protection to address unmet needs in pain management and addiction treatment.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.